Skip to main content
Main navigation
Home
About us
Blog
Become Publisher
FAQs
Cart
Contact
Items per page
50
100
150
200
Market Research Report Title
Publication Date
Pages
Price
Angioedema - Market Insights, Epidemiology and Market Forecast
April 16, 2019
120
USD 6,250.00
Sedation - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Thrombotic Thrombocytopenic Purpura - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Thyroid Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Traveler's Diarrhea - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Secondary Progressive Multiple Sclerosis (SPMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Thrombocytopenia - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Severe Psoriasis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
120
USD 2,250.00
Seizures - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
150
USD 2,250.00
Relapsing Multiple Sclerosis (RMS) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Rhinosinusitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Restless Legs Syndrome - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Rosacea - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Relapsed Chronic Lymphocytic Leukemia (CLL) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Retinal Vein Occlusion - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Rhino-Conjunctivitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Secondary Hyperparathyroidism - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Renal Anemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Seasonal Allergic Rhinitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
120
USD 2,250.00
Pulmonary Embolism - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Malignant Glioma - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Pyelonephritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Primary Immune Deficiency (PID) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Raynauds Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Psoriatic Arthritis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
120
USD 2,250.00
Pulmonary Arterial Hypertension - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
120
USD 2,250.00
Premature Labor (Tocolysis) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Post-Traumatic Stress Disorder (PTSD) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Primary Biliary Cirrhosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Porphyria - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Pouchitis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Premature Ejaculation - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Postherpetic Neuralgia - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Post Menopausal Osteoporosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
120
USD 2,250.00
Spinal Muscular Atrophy (SMA) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Pompe Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Systemic Lupus Erythematosus - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Phenylketonuria (PKU) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Polycystic Kidney Disease - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Systemic Mastocytosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Polycythemia - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Non-Small Cell Lung Cancer - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Systemic Juvenile Idiopathic Arthritis (SJIA) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Spasticity - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Sarcoidosis - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Smallpox - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Tourette Syndrome - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
40
USD 1,500.00
Uterine Leiomyoma (Uterine Fibroids) - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Sleep Apnea - Global API Manufacturers, Marketed and Phase III Drugs Landscape
January 17, 2019
60
USD 2,000.00
Pagination
First page
« First
Previous page
‹‹
Page
1
Page
2
Current page
3
Page
4
Page
5
Page
6
Page
7
Page
8
Page
9
…
Next page
››
Last page
Last »
Subscribe to Drug Pipeline